Your browser doesn't support javascript.
loading
Predicting the outcome of liver transplantation in patients with non-alcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator.
Karnam, Ravikiran S; Punchhi, Gopika; Mitsakakis, Nicholas; Chen, Shiyi; Saracino, Giovanna; Lilly, Leslie; Asrani, Sumeet K; Bhat, Mamatha.
Afiliação
  • Karnam RS; Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
  • Punchhi G; Narayana Health, Bengaluru, India.
  • Mitsakakis N; Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
  • Chen S; Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Saracino G; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
  • Lilly L; Biostatistics Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Asrani SK; Baylor University Medical Centre, Dallas, Texas, USA.
  • Bhat M; Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
Clin Transplant ; 37(4): e14930, 2023 04.
Article em En | MEDLINE | ID: mdl-36762716
BACKGROUND: Non-alcoholic Steatohepatitis (NASH) cirrhosis is the second most common indication for liver transplantation (LT) in the US and often is associated with significant co-morbidities. We validated a model and risk prediction score that reflects the benefit derived from LT for NASH cirrhosis by predicting 5-year survival post-LT. METHODS: We developed a prediction score utilizing 6515 NASH deceased donor LT (DDLT) recipients from 2002 to 2019 from the Scientific Registry of Transplant Recipients (SRTR) database to identify a parsimonious set of independent predictors of survival. Coefficients of relevant recipient factors were converted to weighted points to construct a risk scoring system that was then externally validated. RESULTS: The final risk score includes the following independent recipient predictors and corresponding points: recipient age (5 points for age ≥70 years), functional status (3 points for total assistance), presence of TIPSS (2 points), hepatic encephalopathy (1 point), serum creatinine (5 points if >1.45 mg/dl), need for mechanical ventilation (3 points), and dialysis within 1 week prior to LT (7 points). Diabetes is a stratifying variable for baseline risk. Scores range from 0 to 20 with scores above 13 having an overall survival of <65% at 5 years post-LT. Internal and external validation indicated good predictive ability. CONCLUSION: Our practically useable and validated risk score helps to identify and stratify candidates who will derive the most long-term benefit from LT for NASH cirrhosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article